Eli Lilly and Company , the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results